July 14, 2002 Corporate Influence on Medicine, Healthcare Budgets, Investors FYI Because medicine’s pronouncements are so widely propagated and affect so many people’s lives, corporate influence and manipulation of the truth is more devastating than mere corporate accounting malfeasance. Recent revelations demonstrate how corporate influence and greed – rather than…
Drugging Our Kids – New American Mon, 25 Aug 2003 A powerful article in the current New American holds a mirror to the irresponsible medical involvement of school officials and what has become common practice of forcing children to swallow psychotropic drugs. “Despite the dangers posed by drugs such as…
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Superiority of Zyprexa (Olanzapine) Challenged Mon, 1 Dec 2003 “The profound issue in health care is do we pay anything — regardless of the price — for a statistically significant benefit?” A major 12 month randomized study compared the effectiveness and cost effectiveness of Eli Lilly’s $3.7 billion blockbuster schizophrenia…
Ethics of U Penn surgical “drug implant” experiment Tuesday, October 07 Notwithstanding a legion of prominent bioethicists at major universities such as the University of Pennsylvania and Johns Hopkins University, researchers at these institutions are not deterred from engaging in high risk human experimentation whose ethics are questionable. One has…
FDA Warning Letter: child died from overdose during clinical trial Monday, May 05, 2003 The FDA’s letter of warning to Jacqueline M. Halton, M.D. Children’s Hospital of Eastern Ontario, a participating investigator in a National Cancer Institute pediatric trial describes multiple safety violations–including massive overdoses–that led to the death of…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
“Schizophrenia Digest” Canadian magazine Tue, 3 Jun 2003 Behold the new marketing promo in the guise of “Inspiration and information”….”Schizophrenia Digest” is touted as a magazine directed at schizophrenia patients and families. The publisher, William J. MacPhee, who claims he is taking an antipsychotic, says, “My personal philosophy is that…
AMA Serves Pharma Marketing Priority/ FDA To Add Warnings on ADHD drugs–Concerta, Ritalin, Strattera, Adderall Wed, 29 Jun 2005 The FDA is finally taking note of the fact that many drugs prescribed for the treatment of psychiatric problems are CAUSING serious psychiatric and cardiovascular problems in children and adolescents !…
Recycled drugs: failed antidepressants– Stratera marketed for ADHD; Cymbalta for incontinence Mon, 26 Apr 2004 A front page article in The Wall Street Journal (excerpt below) provides a roadmap of failed Eli Lilly drugs which the company repackaged for a different condition than the one for which the drugs had…
The risks of the drugs far outweigh their benefits, said Vera Sharav, president of the Alliance for Human Research Protection, a New York-based consumer advocacy group.
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
